5 active not recruiting, 3 completed, 3 unknown, 1 recruiting. 4 Not applicable, 4 Phase 2, 3 Phase 1, 1 Phase 3.
Follow ALL, Adult: new trials by email Literature Review of ALL, Adult trials Research Report on ALL, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy Daratumumab Injection - ALL, Adult | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 | 2026-05-13 | |
| Video-recOrded hospItal dischaRge (VOIR) Video recorded shared using a mobile application - ALL, Adult | Not applicable | Unknown | Anglia Ruskin University | 60 | 2024-08-01 | 2024-07-22 |
| RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. Blinatumomab Injection [Blincyto], Doxorubicin - ALL, Adult, Philadelphia-Negative ALL | Phase 2 | Recruiting | Chen Suning | 124 | 2024-02-05 | 2024-04-04 |
| A Study of BN104 in the Treatment of Acute Leukemia BN104 monotherapy, BN104 monotherapy - rp2d - ALL, Adult, AML, Adult | Phase 1 / Phase 2 | Active not recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | 66 | 2023-10-19 | 2026-02-25 |
| Optimising Pharmacist-led Medication Reviews in Primary Care Medication review - ALL, Adult | Completed | University of East Anglia | 15 | 2023-09-12 | 2024-05-13 | |
| Characterizing Sleep Among Long-term Survivors of Childhood Cancer Neurocognitive (Thinking) Testing, CNS Vital Signs (Thinking) Testing, Health Questionnaires, Sleep Surveys & Sleep Diary - ALL, Adult, CNS Tumor | Active not recruiting | St. Jude Children's Research Hospital | 199 | 2023-04-17 | 2026-08-19 | |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Ponatinib + Blinatumomab, Chemotherapy + Imatinib - Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult | Phase 3 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 236 | 2021-09-08 | 2025-01-23 |
| A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL dasatinib plus consolidation chemotherapy with vincristine and prednisone, dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine - Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia | Not applicable | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 60 | 2021-09-06 | 2021-10-01 |
| A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL Dasatinib - Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia | Not applicable | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 80 | 2021-09-06 | 2021-10-01 |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Palliative Care Visits - Leukemia, Acute, AML, Adult | Not applicable | Active not recruiting | University of Virginia | 105 | 2020-08-19 | 2026-05-04 |
| COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being ALL, Adult | Completed | Clinical Nutrition Research Center, Illinois Institute of Technology | 440 | 2020-04-17 | 2023-05-17 | |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT) - B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult | Phase 1 | Completed | Cedars-Sinai Medical Center | 22 | 2020-02-14 | 2025-02-05 |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS CYC140 - AML, Adult, Myelodysplastic Syndromes | Phase 1 | Terminated | Cyclacel Pharmaceuticals, Inc. | 7 | 2019-03-25 | 2024-09-19 |
| Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. Blinatumomab - ALL, Adult | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 71 | 2018-06-04 | 2024-09-19 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Myeloid, Acute (3) · Leukemia (2) · Myelodysplastic Syndromes (2) · Burkitt Lymphoma (1) · Central Nervous System Neoplasms (1)
Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Leukemia, Lymphoid (14) · Lymphatic Diseases (14) · Lymphoproliferative Disorders (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Leukemia (12) · Leukemia, Myeloid (3) · Bone Marrow Diseases (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1)
blinatumomab (4) · Dasatinib (2) · Consolidation Chemotherapy (1) · Cytarabine (1) · Doxorubicin (1) · Drug Therapy (1) · Imatinib Mesylate (1) · Medication Review (1) · Methotrexate (1) · Prednisone (1) · Respiratory Function Tests (1) · VDA-P protocol (1) · Vincristine (1) · daratumumab (1) · ponatinib (1)
First Affiliated Hospital Xi'an Jiaotong University (2) · Anglia Ruskin University (1) · Cedars-Sinai Medical Center (1) · Chen Suning (1) · Clinical Nutrition Research Center, Illinois Institute of Technology (1) · Cyclacel Pharmaceuticals, Inc. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Institut de Recherches Internationales Servier (I.R.I.S.) (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · St. Jude Children's Research Hospital (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · University of East Anglia (1) · University of Virginia (1)
United States (5) · China (4) · Belgium (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Huachao Zhu (2) · Juan Ren (2) · Pengcheng He (2) · Ting Fan (2) · Xiaoning Wang (2) · Ying Chen (2) · A.W. Rijneveld, Dr. (1) · Bei Liu, Dr. (1) · Britt Burton-Freeman, Ph.D (1) · Dengju Li, Prof. (1) · Depei WU, Prof. (1) · Fei Li, Prof. (1) · Gautam Borthakur, MD (1) · He Huang, Prof. (1) · Hui Wei, doctor (1)
2017 (1)